Currently there is no clear guidance for the treatment of moderate risk of pulmonary embolism. The aim of the study is to compare two different therapeutic modalities - standard anticoagulation versus thrombolytic treatment followed by anticoagulation in standard regimen as stated in the pulmonary embolism guidelines.
Standard treatment of moderate risk pulmonary embolism constitutes of sole anticoagulation therapy. In case of troponin positivity and/or echocardiographic findings as i.e. thrombi in RV thrombolytic therapy should be considered. The aim of this trial is to compare the two treatment modalities in their ability to reduce/predict 12 month end-point: pulmonary hypertension, right ventricular failure, exercise capacity.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
100
Silesian Hospital Opava
Opava, Czechia
University Hospital Ostrava
Ostrava-Poruba, Czechia
Clinical manifestations of right ventricular failure and pulmonary hypertension and cardiovascular-related death
The primary outcome of the study is to follow clinical manifestations of right ventricular failure (assessed according to the New York Heart Association /NYHA/ classification).
Time frame: 12 months
Pulmonary hypertension
The primary outcome of the study is to follow pulmonary hypertension (measured in mmHg).
Time frame: 12 months
Cardiovascular-related deaths
The primary outcome of the study is to follow the number of cardiovascular-related deaths within the time frame of 12 months.
Time frame: 12 months
Echocardiographic manifestations of right ventricular failure and pulmonary hypertension.
The secondary outcome measure of the study is to follow echocardiographic manifestations of right ventricular failure (TdiSm).
Time frame: 12 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.